HBIO
Harvard BioscienceBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
The constructive case is that Q1 2026 confirmed margin resilience, the refinancing removed the immediate going-concern overhang, and Project Viking can translate into better throughput and lower fixed costs if execution remains orderly.
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
Capital structure risk: $40M of borrowings plus warrant overhang leaves dilution and refinancing sensitivity in place.
Momentum
94
Value
68
Sentiment
24
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $5.00 · Bull $7.25 · Bear $2.75
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-27 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $4.38
Why
Momentum94 · Δ7d -
Value68 · Δ7d -0.2
Sentiment24 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
94
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
68
32% active weight
Current posture
7d trendFlat
Δ7d
-0.2
Δ21d
-0.2
Sentiment
24
33% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade B. Momentum 93.7 / Value 67.7 / Sentiment 24.0
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$28.87M
Beta
1.55
Shares Out
44.58M
P/E (TTM) · Derived
21.6
P/S (TTM)
0.35
P/FCF (TTM)
4.47
Rev YoY
-6.3%
EPS YoY
+74.9%
Gross Margin
+56.9%
Op Margin
-56.1%
Net Debt
$32.85M
Current Ratio
0.81
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology